Fmr LLC lessened its holdings in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 6.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,786,938 shares of the biopharmaceutical company’s stock after selling 131,654 shares during the period. Fmr LLC owned 1.72% of Juno Therapeutics worth $53,412,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of JUNO. Vanguard Group Inc. raised its stake in Juno Therapeutics by 2.1% during the second quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock worth $187,879,000 after buying an additional 131,864 shares during the last quarter. BlackRock Inc. raised its stake in Juno Therapeutics by 2.6% during the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after buying an additional 110,503 shares during the last quarter. Jennison Associates LLC bought a new position in Juno Therapeutics during the second quarter worth $22,689,000. Geode Capital Management LLC raised its stake in Juno Therapeutics by 8.9% during the first quarter. Geode Capital Management LLC now owns 595,136 shares of the biopharmaceutical company’s stock worth $13,206,000 after buying an additional 48,516 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its stake in Juno Therapeutics by 20.5% during the second quarter. Pictet Asset Management Ltd. now owns 463,435 shares of the biopharmaceutical company’s stock worth $10,766,000 after buying an additional 78,690 shares during the last quarter. Institutional investors own 67.38% of the company’s stock.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,869 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $39.95, for a total value of $514,116.55. Following the completion of the transaction, the executive vice president now directly owns 50,289 shares in the company, valued at approximately $2,009,045.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Klausner sold 12,000 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $30.34, for a total transaction of $364,080.00. Following the completion of the transaction, the director now owns 788,985 shares of the company’s stock, valued at $23,937,804.90. The disclosure for this sale can be found here. Insiders sold a total of 85,004 shares of company stock valued at $3,551,561 over the last 90 days. Company insiders own 15.26% of the company’s stock.

A number of brokerages recently weighed in on JUNO. Vetr downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.47 target price for the company. in a research note on Monday, August 7th. Wells Fargo & Company reissued an “outperform” rating and set a $54.00 target price (up previously from $35.00) on shares of Juno Therapeutics in a research note on Tuesday, September 5th. BidaskClub raised shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, June 20th. Zacks Investment Research raised shares of Juno Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $44.00 target price on shares of Juno Therapeutics in a research note on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the company. Juno Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $37.83.

TRADEMARK VIOLATION WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/17/fmr-llc-sells-131654-shares-of-juno-therapeutics-inc-juno.html.

Shares of Juno Therapeutics, Inc. (NASDAQ JUNO) opened at 42.88 on Tuesday. The company’s market capitalization is $4.50 billion. The firm has a 50-day moving average of $43.16 and a 200 day moving average of $30.34. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $47.03.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. During the same quarter last year, the company posted ($0.64) earnings per share. The firm’s revenue for the quarter was down 22.8% compared to the same quarter last year. On average, equities research analysts expect that Juno Therapeutics, Inc. will post ($3.08) earnings per share for the current year.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.